Corcept Therapeutics Files 8-K
Ticker: CORT · Form: 8-K · Filed: Mar 31, 2025 · CIK: 1088856
| Field | Detail |
|---|---|
| Company | Corcept Therapeutics INC (CORT) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Corcept filed an 8-K on 3/31/25. No major news yet.
AI Summary
Corcept Therapeutics Inc. filed an 8-K on March 31, 2025, reporting other events and financial statements. The filing does not contain specific details on new events or financial figures within the provided text.
Why It Matters
This filing indicates Corcept Therapeutics is providing updates to the SEC, which could include material information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure without immediate negative or positive financial implications mentioned.
Key Players & Entities
- Corcept Therapeutics Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 101 Redwood Shores Parkway (address) — Principal Executive Offices
- Redwood City, CA (location) — Principal Executive Offices City and State
- March 31, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 31, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Corcept Therapeutics Incorporated.
In which state was Corcept Therapeutics Incorporated incorporated?
Corcept Therapeutics Incorporated was incorporated in Delaware.
What is the address of Corcept Therapeutics' principal executive offices?
The address of Corcept Therapeutics' principal executive offices is 101 Redwood Shores Parkway, Redwood City, CA 94065.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 31, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding CORCEPT THERAPEUTICS INC (CORT).